Scienture Holdings, Inc. Overview
Pro stress-test →Scienture Holdings is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system and cardiovascular diseases. The company operates through two segments: Integra (wholesale pharmaceutical distribution) and Scienture (branded pharmaceutical development), targeting unmet healthcare needs with novel specialty products.
Strategic Profile
Pro stress-test →Scienture leverages dual business model combining distribution capabilities with in-house product development. Recent commercial momentum includes FDA-approved Arbli (losartan oral suspension), addressing a $256M market with 71M annual prescriptions, with secured access to over 2,500 healthcare institutions through GPO agreements.
Competitive Landscape
Pro stress-test →Competes in specialty pharma with focus on differentiated formulations in large existing markets. Arbli directly addresses losartan market dominated by established generic competitors (Novartis, Merck generics), but differentiates as first liquid ready-to-use formulation. Faces competition from other oral suspension developers targeting similar patient populations.
Industry Context
Scienture Holdings, Inc. operates in Specialty Pharmaceuticals & Pharmaceutical Distribution.
Key facts
Headquarters: Tampa, Florida · Market cap: $21M